EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ITGB3 promotes cisplatin resistance in osteosarcoma tumors

Qian Li, Guangyou Chen, Huachai Jiang, Haoping Dai, Dongdong Li, Kai Zhu, Kaiquan Zhang, Huarui Shen, Houping Xu, Sen Li iD

Cancer Medicine · 2023-04 · 12 (7) · 8452-8463

DOI: 10.1002/cam4.5585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 11.02.2023. Verfasst von Qian Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, P.R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Osteosarcoma is the most malignant and common primary bone tumor with a high rate of recurrence that mainly occurs in children and young adults. Therefore, it is vital to facilitate the development of novel effective therapeutic means and improve the overall prognosis of osteosarcoma patients via a deeper understanding of the mechanisms of chemoresistance in osteosarcoma progression.

Methods

In this research, the relationship between ITGB3 and the clinical characteristics of patients was detected through analysis of publicly available clinical datasets. The expression of ITGB3 was analysis in collected human osteosarcoma tissues. In addition, the potential functions of ITGB3 in the cisplatin resistance of osteosarcoma cells were investigated in vitro and in tumor xenotransplantation. Finally, the molecular mechanism of ITGB3 in the progression and recurrence of osteosarcoma were explored via transcriptome analysis.

Results

ITGB3 was identified as a potential regulator of tumorigenicity and cisplatin resistance in relapsed osteosarcoma. Furthermore, the decreased osteosarcoma cell proliferation and migration ability in ITGB3 knockout osteosarcoma cells were related to increased apoptosis and slowing cell cycle progression. In addition, ITGB3 had a positive correlation with cisplatin resistance in cells and tumor xenografts in mice. Accordingly, ITGB3 performed the functions of proliferation and cisplatin resistance in osteosarcoma through the MAPK and VEGF signaling pathways.

Conclusion

Our results will contribute to a better understanding of the function and mechanism of ITGB3 in osteosarcoma cisplatin resistance and provide a novel therapeutic target to decrease cisplatin resistance and tumor recurrence in osteosarcoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsOsteosarcomaBone NeoplasmsChildYoung AdultHumansAnimalsMiceCisplatinDrug Resistance, NeoplasmApoptosisNeoplasm Recurrence, LocalCell Line, TumorCell ProliferationIntegrin beta3

Stichwörter der Autor:innen

CRISPR/Cas9ITGB3apoptosiscisplatinosteosarcomatranscriptome

Substanzen

CisplatinAntineoplastic AgentsITGB3 protein, humanIntegrin beta3

Autor:innen und Institutionen

  • The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, P.R. China.

ORCID-Profile: Sen Li

Förderung

  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Li, Q., Chen, G., Jiang, H., Dai, H., Li, D., Zhu, K., Zhang, K., Shen, H., Xu, H., & Li, S. (2023). ITGB3 promotes cisplatin resistance in osteosarcoma tumors. Cancer Medicine, 12(7), 8452-8463. https://doi.org/10.1002/cam4.5585

Vancouver

Li Q, Chen G, Jiang H, Dai H, Li D, Zhu K, et al. ITGB3 promotes cisplatin resistance in osteosarcoma tumors. Cancer Medicine. 2023;12(7):8452-8463. doi:10.1002/cam4.5585

BibTeX
@article{Li2023,
  author = {Li, Qian and Chen, Guangyou and Jiang, Huachai and Dai, Haoping and Li, Dongdong and Zhu, Kai and Zhang, Kaiquan and Shen, Huarui and Xu, Houping and Li, Sen},
  title = {ITGB3 promotes cisplatin resistance in osteosarcoma tumors},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {7},
  pages = {8452--8463},
  doi = {10.1002/cam4.5585}
}
Kostenlos starten →